cancer vaccine

See how a computational pipeline uses next-generation sequencing data to identify genetic alterations that produce cancer-specific antigens.

The field is young, but predicting antigens produced by patients’ malignant cells could yield successful treatments for individuals with a range of cancer types.

There are currently more than two dozen ongoing Phase 1 and Phase 2 trials using different vaccine platforms such as DNA, RNA, synthetic long peptides, and dendritic cells.

The Mount Sinai oncologist studies innate immune cells with the goal of designing novel immunotherapies, including cancer vaccines.

A preliminary clinical trial finds that the personalized therapy improves survival rates and has no severe side-effects.

Stem cells and cancer cells have enough molecular similarities that the former can be used to trigger immunity against the latter.

The treatment also curbed the growth of nearby metastases that did not receive the drug.

In two early trials, vaccines tailored to the mutations in individuals’ cancers appeared to protect 12 of 19 patients against relapse. 

Oncologists have raised concerns about a mouse study that suggests the vaccine for human papillomavirus could cause brain damage.

Phase 3 data from a clinical trial show a positive response to a melanoma treatment based on a modified herpesvirus.

A dendritic cell vaccine targeting melanoma patients’ tumor-specific mutations can activate a broad range of cancer-fighting T cells. 

Armed with the right adjuvant system, vaccines are poised to tackle one of the world’s most intractable diseases. 

Tracking chikungunya virus; reconsidering wood decay-based fungal classification; ASC specks spread inflammation; antibiotic tolerance in E. coli; RIKEN review yields corrections

Mouse study demonstrates the ability of a cancer vaccine targeted against a specific oncogenic mutation to elicit a protective anti-tumor immune response. 

Using patients’ own immune systems to fight cancer

A vaccine that targets 90 percent of all cancers shows promise in early clinical trials.

Lloyd Old, a researcher and former administrator of two cancer research institutes, passed away this week.

A genetically engineered smallpox vaccine improved the survival of liver cancer patients participating in a phase II clinical trial.